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Abstract
Background: Hepatic encephalopathy (HE) is a clinically significant complication of liver cirrhosis impacting on the
patients’ quality of life. Minimal hepatic encephalopathy (MHE) is diagnosed by psychometric tests, found in up to
80 % of patients with liver cirrhosis and carries a high risk of progression to overt HE. Continuous therapy with
rifaximin in combination with lactulose significantly reduces the risk of overt HE, recurrence of HE and HE-related
hospitalizations in randomized, double-blind, placebo-controlled clinical trials. Rifaximin is approved for the therapy
of overt HE in Germany. Treatment with lactulose has been shown to improve cognitive functions in patients with
liver cirrhosis. Data from prospective clinical trials comparing the efficacy of rifaximin alone against a combination
of rifaximin and lactulose in the treatment of MHE are scarce. Changes in the microbiome of the upper and lower
gastrointestinal tract as a result of therapy with rifaximin have not yet been addressed in clinical studies.
Methods and design: RiMINI is a monocentric exploratory pilot study on 60 patients with MHE as assessed by
critical flicker frequency (CFF). Additionally, visual evoked potentials’ (VEP) testing, electroencephalography (EEG) and
psychometric testing (NCT-A) will be carried out. Patients will be randomized to treatment either with rifaximin
alone (550 mg twice daily (bid) continuously for a period of 3 months) or with rifaximin (550 mg bid continuously)
in combination with lactulose (30–60 ml daily) for 3 months. An esophagogastroduodenoscopy (EGD) will be
performed at baseline, at the end of treatment and 6 and 12 weeks after the end of treatment to obtain gastric
and duodenal biopsies and aspirates. The samples will be analyzed for their content of specific bacterial taxae by
applying next generation sequencing (NGS) after rRNA isolation to identify the microbiome of the stomach and
duodenum, and of the gut, in patients with liver cirrhosis and MHE before and after therapy.
Discussion: Differences of the effect of antibiotic therapy with rifaximin alone or in combination with lactulose on
the clinical course of MHE are assessed.
Trial registration: The trial was registered as DRKS00006359 on March 17th 2015, with the universal trial number
U1111-1163-9410 and with EudraCT2013-004414-18.
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Background
Hepatic encephalopathy (HE) is defined as an unspecific
brain function disorder, due to either failure of (cirrhotic)
liver function or to port osystemic shunting and thus
by-passing the functional parenchyma. For an accurate
diagnosis of HE, other brain diseases have to be prop-
erly excluded. HE is characterized by cognitive, psychi-
atric and/or motoric impairment [1] leading to changes
in the circadian rhythm, atmospheric fluctuations,
phased loss of concentration, increased forgetfulness, ir-
ritability, and somnolence up to hepatic coma [2]. Sub-
clinical neurological deficits are defined as minimal
hepatic encephalopathy (MHE). The presence and de-
gree of (M)HE can only measured by psychometric tests
and clinically apparent deficits, graded by the West
Haven criteria [1, 3]. Clinically apparent (i.e., overt) HE
is estimated to be present in 30–45 % of patients with
liver cirrhosis and leads to frequent hospitalization, im-
pairment of health-related quality of life (HRQL) and
ability to work [4]. Up to 80 % of cirrhotic patients
present with MHE with cognitive dysfunction in special
diagnostic testing [5, 6, 7]. In patients with MHE activ-
ities of daily life are affected resulting, among other
problems, in an increased risk for accidents when driv-
ing and navigating [8]. The clinical manifestations of HE
in each stage are potentially reversible by adequate
therapeutic management. MHE is currently under-diag-
nosed in patients with liver cirrhosis and carries a high po-
tential for progression to overt HE. Current therapies are
directed at the reduction of ammonia production from the
gastrointestinal tract by administration of the non-
absorbable disaccharide lactulose and the non-absorbable
antibiotic rifaximin [9–18].
Rationale for the explorative study
Continuous therapy with rifaximin in combination with
lactulose significantly reduces the risk of overt HE, re-
currence and HE-related hospitalization in randomized
double-blind placebo-controlled clinical trials [1–3].
Rifaximin is approved for the therapy of overt HE in
Germany. Therapy with lactulose has been shown to im-
prove cognitive functions in patients with liver cirrhosis.
So far, whether monotherapy with rifaximin is as effect-
ive as combination therapy with rifaximin and lactulose
in the treatment of MHE, has not been addressed in a
prospective clinical trial.
Rifaximin is a minimally absorbed gut-selective anti-
biotic and thus impacts on the intestinal microbiome.
The role of the intestinal microbiome in the pathophysi-
ology of HE is still little understood. To our knowledge,
changes in the microbiome of the upper gastrointestinal
(GI) tract as result of therapy with rifaximin have not
yet been addressed in clinical studies and studies
addressing the persistence of changes of the intestinal
microbiome are scarce [19].
Methods and design
RiMINI is a monocentric exploratory pilot study on 60
patients with MHE as assessed by critical flicker frequency
(CFF) analysis. Additionally, visual evoked potentials’
(VEP) testing, electroencephalography (EEG) and a psy-
chometric test (NCT-A) will be carried out. The patients
will be randomized to treatment either with rifaximin
alone 550 mg twice daily (bid) continuously for a period
of 3 months or to continuous treatment with 550 mg
rifaximin bid in combination with lactulose 30–60 ml
daily (to pass 2–3 semisoft stools/day) for 3 months. An
esophagogastroduodenoscopy (EGD) will be performed at
baseline, at the end of antibiotic treatment, as well as 6
and 12 weeks after the end of treatment to obtain gastric
and duodenal biopsies and aspirates will be taken. The
samples will be analyzed for their specific bacterial taxae
by applying next generation sequencing (NGS) after ribo-
nucleic acid (RNA) isolation. Additionally, stool samples
will be taken at the same time points. Prevalence of Heli-
cobacter pylori, which is the predominant gastric microbe,
will be assessed by histology, rapid urease test and ser-
ology at study entry. For clinical assessment, quantifica-
tion of MHE and therapeutic effects, CFF, EEG, VEP and
psychometric tests are assessed weekly during the first
month and every 4 weeks from the beginning of the sec-
ond month until the end of the post-treatment follow-up.
Changes in the gut microbiome from antibiotic ther-
apy with rifaximin alone or rifaximin with lactulose are
analyzed comparing pre- and post-antibiotic time points.
The follow-up data will show whether the change in the
gut microbiome is persistent or transient. We will com-
pare the effect of antibiotic therapy with rifaximin alone
with a combination therapy with lactulose on the clinical
course of MHE. As planned, NGS methods (Illumina se-
quencing, Illumina, San Diego, CA, USA) will be used to
characterize the composition and changes of both stom-
ach and small bowel microbiomes. Bacterial ribosomal
ribonucleic acid (rRNA) will be isolated from aspirates,
biopsies and feces and then stored in RNAlater at −80 °C.
The samples will be analyzed by NGS methods as de-
scribed below with the aim of identifying the microbiome
of the stomach and the small bowel, as well as of the large
bowel, in patients with liver cirrhosis and MHE and its
changes before and after therapy (Fig. 1).
Methods for studying intestinal microbiota
Samples will be taken following a strict algorithm. Aspi-
rates will be collected using a sterile, straight endoscopic
retrograde cholangiography (ERC)-catheter via a stand-
ard gastroscope (Olympus 180). After collecting the as-
pirate from the duodenum (pars descendens), biopsies
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will be taken from this area after removal of the catheter.
Afterwards gastric juice will be aspirated using a second
sterile catheter. Biopsies will be taken from the antral re-
gion of the stomach for RNA extraction. Additional bi-
opsies for histopathological examination, rapid urease
testing and culturing of H. pylori, if infected, will be
taken from the duodenum, the gastric antrum, the angu-
lus and the gastric corpus. After completion of the endo-
scopic procedure, a saliva sample will be taken directly
from the oral cavity of the patients. All samples deter-
mined for RNA extraction will be stored directly in 1 ml
RNAlater (Sigma-Aldrich, St. Louis, MO, USA) and kept
at room temperature for at least 4 hours (maximum 8
hours). Afterwards, samples will be stored at −80 °C.
RNA will be extracted from the aspirates, feces and biopsies
using the RNeasy Mini Kit following the manufacturer’s
instructions (Qiagen, Hilden, Germany). In summary: the
biopsies will be relocated from the RNAlater into buffer
solution as specified, whereas the liquids will be centri-
fuged for 10 minutes at 15,000 rpm and 4 °C and resus-
pended into buffer solution. The solutions will be replaced
in Lysing Matrix E tubes and the cells will be lysed
and homogenized using a Fast Prep™-24 instrument
(MP Biomedicas, Solon, OH, USA) for 2 × 45 seconds,
interrupted by a 1-minute ice cooling break. Addition-
ally, we will complement a second digestion of deoxy-
ribonucleic acid (DNA) on the columns using the
RNase-Free DNase Set (Quiagen, Hilden, Germany)
working with 70 μl RDD buffer and 10 μl DNase for
each sample for 8 minutes. Finally, the RNA will be
eluted in 32 μl RNase-free water.
To synthesize first-strand complementary deoxyribo-
nucleic acid (cDNA) the SuperScript® III First-Strand
Synthesis System (Invitrogen™, Carlsbad, CA, USA) will
be used following the manufacturer’s instructions.
The V1–V2 region of the 16S rRNA gene will be amp-
lified using primers based on 27F and 338R primers.
The primers include sequences complementary to the
Illumina-specific adaptors to the 5′ends that are used in
the course. Amplification will be performed in a total
volume of 50 μl with 5x PrimeSTAR TM buffer (Clon-
tech Laboratories, Mountain View, CA, USA). Each
deoxyncleoside triphosphate will be contained at a con-
centration of 2.5 mM and each primer will be contained
at a concentration of 0.2 μM. One microliter of cDNA
template will be used with 0.5 μl PrimeSTAR TM HS
DNA polymerase (2.5 U, Clontech Laboratories, Moun-
tain View, CA, USA). The polymerase chain reaction
(PCR) will be started with an initial denaturation step of
95 °C for 3 minutes, followed by 15 cycles of denatur-
ation at 98 °C for 10 seconds, annealing at 55 °C for 10
seconds and extension at 72 °C for 45 seconds. Non-
template control (water) and positive control (Staphylo-
coccus aureus DSM3463) were used to exclude contami-
nants and systematic errors. A second PCR will be
performed using 1 μl reaction product under the same
conditions for 20 cycles using PCR primers designed to
integrate the sequence of the specific Illumina multiplex-
ing sequencing primers and index primers. Negative con-
trol (water) will document the absence of contaminants.
Following the third PCR amplicons will be verified by
agarose gel electrophoresis and purified using Macherey-
Nagel 96-well plate purification kits (Macherey-Nagel,
Düren, Germany) following the manufacturer’s instruc-
tions. The products will be quantified with the Quant-iT
PicoGreen double-stranded deoxyribonucleic acid dsDNA)
reagent and the associated kit (Invitrogen, Darmstadt,
Germany).
Amplicon libraries will be prepared by pooling equi-
molar ratios of amplicons (200 ng/sample). After com-
bining five libraries with unique barcode primers and
different index primers, a second precipitation step will
be performed to remove any contaminants. The super-
natant will be removed, air dried and resuspended in 30 μl
of double-distilled water. The product will be separated
on a 2 % agarose gel. PCR products of the correct size will
Fig. 1 Study flow chart
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be extracted and recovered using the QIAquick gel extrac-
tion kit (Qiagen, Hilden, Germany). Libraries will be sent
for 150-nt paired-end sequencing on a GAIIX Genome
Analyzer (Illumina, San Diego, CA, USA).
The sequencing analyses will be followed by bioformati-
cal analyses using Primer7 (Primer-E Ltd, Lutton, United
Kingdom).
Primary objective
This study primarily aims at the analysis of the efficacy
of MHE therapy with rifaximin alone or in combination
with lactulose on the improvement of neuropsycho-
metric and neurophysiological changes.
Secondary objective
Composition and changes in the composition of the in-
testinal microbiome of the upper GI tract, as well as of
the large bowel, before, during and after therapy of
MHE with either a combination of lactulose and rifaxi-
min or rifaximin monotherapy are the focus of further
analyses.
Eligibility/Description
Patients of either sex are eligible for this trial provided
they meet all inclusion and exclusion criteria.
Inclusion criteria
Individuals who are suitable to participate as determined
by the outcome of medical history, physical assessment,
and clinical judgment of the investigator can be included
into the study.
In order to participate in this study, all subjects must
meet all the following inclusion criteria in the “All sub-
jects” section below.
All subjects
Men and women in the age range 18–90 years at the
time of enrollment and who are mentally competent,
willing and able to understand the nature and risks of
the proposed study, and able to sign the consent form
prior to study entry. The individuals must have a pro-
jected life expectancy of 6 months or longer and must
be able to comply with all study procedures and require-
ments. Women with childbearing potential must have a
negative pregnancy test during the screening period. The
diagnosis of liver cirrhosis is needed, established either
by histology or by typical signs on transabdominal ultra-
sound in combination with signs of portal hypertension
(ascites, enlarged spleen, fundic or esophageal varices),
and the presence of MHE has to be confirmed. To con-
firm the diagnosis of MHE the following tests will be
performed: number-connection test A (NCT-A), critical
flicker frequency analysis (CFF), electroencephalography
(EEG), and visual evoked potentials (VEP) whereby the
final confirmation of MHE depends on the CFF result
(CFF <39 Hz). The additional neurophysiological and
neuropsychometric tests will be analyzed concerning
diagnostic utility alone or in combination.
Exclusion criteria
Individuals with any of the following medical conditions
are excluded from participation in the trial:
Any documented underlying allergic condition against
rifaximin or lactulose, underlying blindness or eye axis
deviation or red-green color blindness. The presence of
overt HE rules out participation in the study. Antibiotic
treatment within 28 days before study entry or during
the study constitutes an exclusion criterion. Individuals
who are not sufficiently healthy as determined by med-
ical history, physical assessment, and clinical judgment
of the investigator are excluded. Individuals who are
unable to follow the required study procedures for the
whole period of the study and/or who have behavioral
or cognitive impairment or psychiatric disease that, in
the opinion of the investigator, may interfere with the
subject’s ability to participate in the trial, are excluded.
Individuals who are expected to be hospitalized (except
for endoscopic therapy of esophageal varices) or
undergo surgery during the study period or who have
participated in another clinical study within 30 days
prior to enrollment into the study are not allowed to
participate. Individuals with ongoing drug or alcohol
abuse that, in the opinion of the investigator, would
interfere with the subjects’ safety or the evaluation of
the study objectives, and individuals who are member
of the research staff or have relatives who are member
of the research staff, are excluded. Women with child-
bearing potential who have a positive pregnancy test
(positive urine or serological (beta HCG)), and pregnant
or lactating women are not allowed to participate as are
women who are unwilling to use an acceptable method of
birth control up to visit 4. Acceptable methods of birth
control include (1) established use of oral, injected or im-
planted hormonal methods of contraception: placement of
an intrauterine device or intrauterine system, (2) barrier
methods of contraception: condom or occlusive cap (dia-
phragm or cervical/vault caps) with spermicidal foam/gel/
film/cream/suppository, (3) male sterilization (with the
appropriate post-vasectomy documentation of the absence
of sperm in the ejaculate), (4) true abstinence from hetero-
sexual sexual intercourse: when this is in line with the pre-
ferred and usual lifestyle of the subject. (Periodic
abstinence (e.g., calendar, ovulation, symptothermal, post-
ovulation methods) and withdrawal are not acceptable
methods of contraception). Individuals with a medical his-
tory of any illness that may, in the opinion of the investi-
gator, pose additional risk to the subject due to
participation in the study, are also excluded.
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Prior and concomitant medication
Patients may receive concomitant therapy during the
study as required. Any concomitant medication at base-
line as well as any changes made in concomitant medi-
cation within the study period (until the last follow-up
examination) will be recorded in the electronic Case
Report Form (eCRF). All concomitant therapy will be
recorded using generic names. The necessity to use
antibiotic therapy besides rifaximin leads to exclusion
from this study.
Schedule of evaluations/Estimated timelines
This study consists of three phases: (1) the screening
phase, (2) the treatment phase and (3) the follow-up
phase (Table 1).
Recruitment
Patients will be recruited in the hospital department
where they are treated for their primary disease. This
will usually be the Department of Gastroenterology,
Hepatology and Infectious Diseases of the University
of Magdeburg, Germany. Patients will be informed
by the investigator or a sub-investigator about the
scope and the goals of this trial on the basis of the
study-specific patient information leaflet and are
then invited to participate. Any study-related meas-
ure (including diagnostic screening procedures) will
only take place after the patient has personally signed
and dated the study-specific informed consent form.
Patients will have at least 24 hours to consider their
participation in this trial before signing the informed
consent form.
Randomization procedure
The randomization will be performed with the clinical
database software secuTrial that is also used for the data
management in the study. The two arms will be ran-
domized in a 1:1 ratio using the minimization method
described by Pocock and Simon with a stratification
for age and gender.






Treatment phase EOT 6 weeks after EOT 12 weeks after
EOT = End of study
Time Day −15 –day 0 0 (visit 0) Days 1–90
(visits 1–3)
−3d to +3d










X x X x X
Physical exam,
vital signs, weight




X x x X x X
Blood tests including
pregnancy test
X x x X x X






Treatment phase EOT 6 weeks after EOT 12 weeks after
EOT = End of study
Time Day −15–day 0 0 (visit 0) Days 1–90
(visits 1–3)
−3d to +3d






H. pylori serology x
Stool samples x x x x x
Rapid urease test x
Assessment of
neurocognitive function





CFF critical flicker frequency, ECG electrocardiogram ECOG Eastern Cooperative Oncology group, EEG electroencephalogram, EGD esophagogastroduodenoscopy,
EOT end of treatment, NCT-A number-connection test A, QOL quality of life, VEP visual evoked potentials
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Blinding
Due to the study concept (pills versus pills + liquids) a
(double-)blinded concept appeared inoperable: therefore,
the study will be performed as an open label study. The
use of objective neuropsychometric measurements
without learning curves ensures a maximum decrease of
confounding effects.
Withdrawal and replacement criteria for treatment
Every patient has the right to refuse further participation
in the study at any time and without providing any rea-
sons. A patient’s participation will be terminated imme-
diately upon their request. The investigator should seek
to obtain the reason and record this in the eCRF. This
study is designed as an intention-to-treat (ITT) study.
Safety assessment
Patient safety will be assessed at every visit until the end
of treatment. They will be monitored for adverse events
(AEs) using NCI-CTCAE V4.0 criteria. All AEs are to be
documented in the eCRF. In cases of serious adverse
events (SAEs), the event is also to be documented on
the SAE form provided by the sponsor. The SAE man-
agement will be conducted by the Clinical Study Center.
The processes are described in a separate SAE Manual.
Annually, a development update safety report (DSUR)
must be submitted to the competent authority (BfArM).
Statistical analysis
All demographic and baseline variables are presented in
descriptive statistics stratified by treatment arm in the
full analysis set (FAS, all randomized patients). Explora-
tory tests, according to the level of the respective vari-
ables, will search for differences between both arms
which might occur despite randomization. The primary
target variable is compared between both treatment
arms. The odds ratio for treatment success is calculated
between both treatment arms together with the corre-
sponding two-sided 95 % confidence interval. If the confi-
dence interval is completely above or below the threshold
of 1, the superiority of the corresponding treatment arm
with larger success rates can be concluded. If the confi-
dence interval covers the threshold of 1, then the lower
and upper confidence limits give limits which can be used
in non-inferiority statements. This analysis is performed
primarily in the modified full analysis set (MFAS, all ran-
domized patients but excluding those with missing CFF
tests) according to the ITT principle. Missing values are
imputed by the last observation carried forward principle.
Secondary analyses for the primary target variable in-
clude (1) logistic regression analysis with treatment arm,
sex, age and baseline value of CFF as co-variables, (2) ana-
log analyses in the per protocol set (PPS, patients of the
MFAS excluding those with severe protocol violations),
(3) analog analyses for the result of CFF at end of follow-
up, (4) description of the results of the psychometric tests
(mean and standard deviation) per treatment arm and
comparison in two-sample t tests (both at end of treat-
ment and end of follow-up).
The secondary efficacy variables are compared be-
tween the treatment arms in analysis of covariance
(ANCOVA) models with treatment arm, sex, age and
respective baseline variable as factors or co-variables,
respectively.
Safety analysis is done in the safety set (SS, patients re-
ceiving at least one treatment) in descriptive and ex-
ploratory analyses. Laboratory variables and rates of
SAEs are compared between both treatment arms using
the Mann-Whitney U test and Fisher’s exact test.
Power analysis
This is an exploratory pilot study as so far data on the
monotherapeutic effect of rifaximin in the treatment of
MHE are scarce. The results will give the basis for plan-
ning a later confirmatory multicenter trial. With the
given sample sizes the proof of differences between the
two treatment options, or of acceptable non-inferiority
margins, can be expected only if the additional of lactu-
lose drastically improves the success rates of the rifaxi-
min treatment.
Ethics
The planning and conduct of this clinical study are sub-
ject to national laws. The study will be conducted in ac-
cordance with the protocol and the ethical principles
that have their origin in the Declaration of Helsinki and
the International Conference on Harmonization guide-
lines for Good Clinical Practice (ICH-GCP) [20, 21].
The study protocol and any amendments have been
reviewed and approved by the ethic committee of the Otto-
von-Guericke University of Magdeburg, Germany, and by
the competent authority, BfArM, before implementation.
Data handling, data processing, monitoring and auditing
Data required according to this protocol are to be
recorded in the eCRFs in a timely manner. A Data
Manual (DM) will be maintained specifying all relevant
aspects of data processing for the study (including data
validation, cleaning, correcting, releasing).
For data coding (e.g., AEs, baseline findings, medica-
tion, medical/surgical history), internationally recognized
and accepted dictionaries will be used.
All monitoring activities will be overseen by the coord-
inating study bureau. A member of the sponsor’s (or
designated chief research officer’s (CRO’s) quality assur-
ance unit may visit the investigator annually in order to
audit the performance of the study at the study site and
the study documents originating there.
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In addition, inspections by health authority representa-
tives – including foreign authorities – and Institutional
Ethical Committees (IECs) and Institutional Review
Boards (IRBs) are possible at any time.
Discussion
Rifaximin treatment for patients with overt HE has been
shown to be effective in the amelioration of cognitive
function and in the prevention of recurrence of overt
HE [14]. In patients with MHE rifaximin significantly
improves cognitive function and HRQL [13, 14]. However,
more than 90 % of patients with HE treated in prospective
studies received a combination therapy of rifaximin and
lactulose. Only a single prospective trial with a limited
number of subjects addressed the effect of rifaximin on
MHE [13]. The primary objective of our study, therefore,
is to analyze the efficacy of rifaximin alone or in combin-
ation with lactulose on the improvement of neuropsy-
chometric and neurophysiological changes in patients
with MHE. Although current therapeutic concepts in
the treatment of HE are directed to reduce bacterial am-
monia production by antibiotic treatment, the role and
contribution of the upper-GI microbiota in the patho-
genesis of HE remain poorly understood. The secondary
objective of this study aims at evaluating the microbial
diversity and the composition of the microbiota in the
upper GI tract, and in the stool, in cirrhotic patients
with and without MHE before, during, and after therapy
to assess the degree of changes and whether they are
transient or persistent.
Trial status
This trial is currently recruiting patients. The first patient
was randomized on 24 April 2015.
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